We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Prescription medication — not a dietary supplement
Minoxidil (oral & topical)is a prescription (or investigational) drug, not a supplement. It is included here for reference because people research and discuss it (often used off-label) — not as a recommendation. Take it only under a qualified clinician's supervision and only as prescribed; do not source it from grey-market vendors, where identity, purity, and dosing are unverified. The evidence below reflects its clinical trials.
What the evidence says
Most Minoxidil (oral & topical) studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality meta-analyses and randomised trials published 2002–2025 with a typical study size of 352 participants.
Based on 8 studies · 1 meta-analysis · 4 RCTs · 3,004 total participants
Confidence
ModerateBy outcome
Minoxidil (oral & topical) has an evidence score of 5.5/10 — emerging evidence based on 8 indexed studies, including 1 meta-analysis. A potassium-channel-opening vasodilator — originally an oral antihypertensive — whose well-documented hypertrichosis side effect made it the first FDA-approved hair-loss drug. Topical 2–5% (Rogaine) is OTC and proven in androgenetic alopecia; low-dose ORAL minoxidil (LDOM, ~0.25–5 mg) is an off-label, rapidly adopted alternative with real but generally mild cardiovascular/hypertrichosis side effects. A drug, not a supplement — and not a longevity compound. Representative study: PMID 39425514.
The commonly studied dose of Minoxidil (oral & topical) is Topical 2–5% solution or 5% foam applied to the scalp (men: 5% twice daily or once-daily foam; women: 2% twice daily or 5% foam once daily). Low-dose ORAL minoxidil is off-label and clinician-titrated, typically 0.25–5 mg once daily. A drug — not an approved supplement regimen.. Individual needs vary — start at the lower end of the range and adjust based on how you respond.
Finasteride
Mostly mechanism / observationalA prescription 5α-reductase type-II inhibitor that lowers DHT to treat male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). The hair and prostate benefits are well-proven in large RCTs. The honest caveats are real and prominent: sexual side effects (erectile dysfunction, decreased libido) in a minority of men, a disputed but important 'post-finasteride syndrome' with persistent symptoms, and a depression/suicidality safety signal in pharmacovigilance data. It is NOT a longevity drug.
Last reviewed June 2026 · evidence from 8 studies · how we score
This information is for educational purposes only. It is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any supplement or medication.
Minoxidil — topical (Rogaine) & low-dose oral (LDOM) for hair loss
A potassium-channel-opening vasodilator — originally an oral antihypertensive — whose well-documented hypertrichosis side effect made it the first FDA-approved hair-loss drug. Topical 2–5% (Rogaine) is OTC and proven in androgenetic alopecia; low-dose ORAL minoxidil (LDOM, ~0.25–5 mg) is an off-label, rapidly adopted alternative with real but generally mild cardiovascular/hypertrichosis side effects. A drug, not a supplement — and not a longevity compound.
Topical minoxidil has FDA-grade double-blind RCT evidence for androgenetic alopecia in both men and women, and low-dose oral minoxidil now has supportive head-to-head RCT, meta-analysis, and large safety-cohort data — but it is a suppressive treatment (benefit reverses on stopping), the oral route is off-label with real systemic vasodilator side effects (hypertrichosis, fluid retention, tachycardia), and it is a hair-loss drug, not a longevity compound.
Minoxidil is a potassium-ATP (K-ATP) channel opener that was developed as a potent oral antihypertensive (Loniten). Its near-universal side effect — hypertrichosis, unwanted body-hair growth — was repurposed into the first FDA-approved treatment for pattern hair loss.
Minoxidil is a prodrug: scalp sulfotransferase enzymes convert it to the active minoxidil sulfate, which opens K-ATP channels, promotes dermal-papilla vasodilation/perfusion, and prolongs the anagen (growth) phase of the hair follicle — which is why sulfotransferase activity partly predicts who responds.
Topical minoxidil 2% and 5% (solution or foam) is OTC-approved and supported by large double-blind RCTs in men and women: 5% outperforms 2% in men (Olsen 2002) and the 5% foam works in both sexes (a head-to-head trial found once-daily 5% foam numerically comparable to twice-daily 2% solution in women, though it did not formally meet its noninferiority margin).
The newer story is low-dose ORAL minoxidil (LDOM, typically 0.25–5 mg daily): off-label and Rx-only, it has been adopted rapidly because adherence is easier than twice-daily topical application.
A head-to-head RCT (Penha 2024, JAMA Dermatology) found oral 5 mg comparable to topical 5% in men, and a meta-analysis of oral-vs-topical RCTs found no significant difference in hair density.
The honest framing: minoxidil genuinely regrows hair, but it is suppressive (benefit reverses on stopping), and oral dosing carries systemic effects from the same vasodilator mechanism — hypertrichosis is the most common reason for discontinuation, and fluid retention, lightheadedness, and tachycardia occur in a small percentage; the historical high-dose antihypertensive literature documents fluid retention and, rarely, pericardial effusion.
Large safety cohorts (Vañó-Galván 2021, n=1404; the hypertension/arrhythmia cohort) show LDOM is generally well tolerated at hair-loss doses, but it is a cardiovascular drug being used cosmetically, not a geroprotector.
The score reflects strong, FDA-grade efficacy evidence for topical and good emerging RCT/cohort evidence for oral, against a suppressive (lifelong) treatment model and real systemic side effects with the oral route.
Minoxidil is a prodrug — scalp sulfotransferase enzymes convert it to active minoxidil sulfate; sulfotransferase activity partly predicts who responds.
Minoxidil sulfate opens potassium-ATP channels, relaxing vascular smooth muscle — driving both dermal-papilla perfusion and the systemic blood-pressure effect.
Promotes a longer growth (anagen) phase and vellus-to-terminal hair conversion, increasing hair count and shaft diameter.
How Minoxidil (oral & topical) works — from molecular targets to health outcomes. Click an edge to see supporting research.This visualization is in beta — pathways are being refined and expanded.
Tap node to isolate • Pinch to zoom • Tap edge for research
Topical 2–5% solution or 5% foam applied to the scalp (men: 5% twice daily or once-daily foam; women: 2% twice daily or 5% foam once daily). Low-dose ORAL minoxidil is off-label and clinician-titrated, typically 0.25–5 mg once daily. A drug — not an approved supplement regimen.
Can be taken without food
| Form | Type |
|---|---|
| 🧴Topical 5% foam/solution (OTC) for most; low-dose oral minoxidil under a clinician for poor topical responders | Recommended |
| 💊Finasteride/dutasteride (different mechanism — 5-alpha-reductase inhibition); often combined with minoxidil | Alternative |
Topical is OTC-approved; oral is off-label and prescription-only.
Minimum: 12 weeks
Optimal: 24 weeks
Cycling: Not required
Note: Effects take 3–6 months; an initial shedding phase is common. Benefit is suppressive — it reverses within months of stopping, so treatment is ongoing.
Dose-response data unavailable. The current published research for Minoxidil (oral & topical) does not provide sufficient dose-specific outcome data to generate reliable dose-response curves.
Refer to the Dosage & Timing section above for recommended dose ranges based on available evidence.
Topical 2–5% increases hair count vs placebo in androgenetic alopecia; 5% outperforms 2% in men.
Low-dose oral minoxidil regrows hair comparably to topical with easier once-daily adherence.
Excess body/facial hair is the most common effect of oral minoxidil and the top reason for stopping.
Vasodilation can cause fluid retention, lightheadedness, ankle edema, and tachycardia, especially orally; rare pericardial effusion at high antihypertensive doses.
Oral LDOM needs clinician oversight and dose titration; monitor for edema and tachycardia.
Oral minoxidil commonly causes facial/body hypertrichosis — set expectations; topical may be preferred.
Avoid — minoxidil is not recommended in pregnancy/lactation.
Additive blood-pressure lowering and fluid retention with oral minoxidil.
Oral minoxidil with guanethidine can cause profound orthostatic hypotension.
Tip: Most common effect of oral minoxidil and top reason for stopping; dose reduction and hair removal help.
Tip: From vasodilation; more common at higher oral doses — monitor weight/edema; a diuretic is sometimes co-prescribed.
Tip: Titrate the oral dose slowly; caution in those with cardiovascular disease.
Tip: Often the propylene-glycol vehicle — switching to 5% foam usually resolves it.
Tip: Documented mainly with high-dose antihypertensive use, not low-dose hair dosing; clinician monitoring if cardiac risk.
The best time to take Minoxidil (oral & topical) is in the morning. It can be taken on an empty stomach. Oral LDOM is taken once daily and is clinician-titrated from a low dose; topical is applied to a dry scalp once or twice daily and left on.
Minoxidil (oral & topical) should be used with caution — talk to a healthcare provider before taking it. The most commonly reported side effects are hypertrichosis (unwanted hair growth), fluid retention / ankle edema, lightheadedness / tachycardia. Use caution if any of these apply to you: Pheochromocytoma (oral — vasodilator); Significant uncontrolled cardiovascular disease without clinician oversight (oral); Known hypersensitivity to minoxidil or vehicle (e.g., propylene glycol in some topicals).
Dutasteride
Mostly mechanism / observationalA dual 5α-reductase (type I + II) inhibitor approved for benign prostatic hyperplasia and used off-label for male pattern hair loss. It suppresses DHT more deeply than finasteride (which blocks only type II), and head-to-head it beats finasteride for hair regrowth. It carries the same sexual and mood side-effect concerns as finasteride — with a much longer half-life, so any persistent effects clear more slowly. A prescription drug, not a supplement, and not a longevity drug.